1-5 of 5
James Dugan, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1, Open Label Dose Escalation Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Guillermo Garcia-Manero, MD, Uwe Platzbecker, Stefano R. Tarantolo, MD, Stefanie Gropper, Chetasi Talati, MD, Katharina S. Götze, James Dugan, MD, Eric S. Winer, MD, Elizabeth Martinez, PhD DHSC, MSN, Christopher Lieberman, Reinhard von Roemeling, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 16.
https://doi.org/10.1182/blood-2020-140889
Published: 2020
Journal Articles

PTPN11 Mutations Confer Unique Metabolic Properties and Increase Resistance to Venetoclax and Azacitidine in Acute Myelogenous Leukemia

Brett M. Stevens, PhDBS, Courtney L Jones, PhD, Amanda Winters, MDPhD, James Dugan, MD, Diana Abbott, PhD, Michael R. Savona, MD, Stephen W. Fesik, PhD, Daniel A Pollyea, MD, Craig T Jordan, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 909.
https://doi.org/10.1182/blood-2018-99-119806
Published: 2018
Journal Articles

Relapsed Acute Myeloid Leukemia Is Less Sensitive to Venetoclax + Azacitidine Due to Leukemia Stem Cell Resistance Driven By Fatty Acid Metabolism and Can be Overcome By Pharmacologic Inhibition of CPT1

Daniel A Pollyea, MD, Courtney L Jones, PhD, Brett M Stevens, PhD, Shanshan Pei, PhD, Angelo D'Alessandro, PhD, Rachel Culp-Hill, BS, Diana Abbott, PhD, Andrew Hammes, MS, James Dugan, MD, Jonathan A Gutman, MD, Enkhtsetseg Purev, MD PhD, Clayton Smith, MD, Craig T Jordan, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 432.
https://doi.org/10.1182/blood-2018-99-111507
Published: 2018
Journal Articles

Bone Marrow Cellularity and Recovery of Blood Counts after Venetoclax and Azacitidine in Elderly Acute Myeloid Leukemia Patients Unfit for Induction Chemotherapy

James Dugan, MD, Daniel A. Pollyea, MD, Diana Abbott, PhD, Theodore Schultheiss, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5086.
https://doi.org/10.1182/blood.V130.Suppl_1.5086.5086
Published: 2017
Journal Articles

Epstein-Barr Virus Kinase-Targeted Therapy for Primary Central Nervous System Post-Transplant Lymphoproliferative Disorder

James Dugan, MD MS, Bradley M. Haverkos, MD MPH, Ludmila Katherine Martin, MD, Marisa F. Martin, Mark E Lustberg, MD PhD, John T. Patton, PhD, Gerard Nuovo, MD, Fengting Yan, MD, PhD, Robert Cavaliere, MD, Shannon C. Kenney, MD, Joyce Fingeroth, MD, Gerard Lozanski, MD, Juan Carlos Ramos, MD, Pierluigi Porcu, MD, Michael A. Caligiuri, MD, Robert A. Baiocchi, MD PhD
Journal: Blood
Blood (2014) 124 (21): 1750.
https://doi.org/10.1182/blood.V124.21.1750.1750
Published: 2014